Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2017

View Archived Issues

NewLink Genetics synthesizes indoximod prodrug for cancer immunotherapy

Pan-TRK inhibitor CH-7057288 active against TRK fusion-driven cancer in vivo

Discovery and clinical data detailed for IDO-1 inhibitor BMS-986205

DS-5141 designated under Japanese Sakigake designation system

Phase Ib/II topline results for Resolaris in early-onset facioscapulohumeral muscular dystrophy

Preliminary results from the SIGNAL trial of VX-15 in Huntington's disease

Cara reports encouraging data from phase I safety trial of intravenous CR-845

Kissei discontinues development of KCT-0809 for dry eye associated with Sjogren's syndrome

BD set to acquire Bard

CMV pp65-LAMP vaccination results in survival benefit in patients with glioblastoma

Akari presents new data on Coversin

Clinigen and Onxeo agree to launch managed access program for Beleodaq in Europe

Xoma reports phase II results for X-213 in prolactin inhibition

EMA committee recommends approval of Skilarence for psoriasis

Auris Medical reports results from Keyzilen extension study AMPACT2 in acute inner ear tinnitus

MONARCH 3 trial of abemaciclib in breast cancer meets primary endpoint

Aducanumab designated under Japanese Sakigake designation system for Alzheimer's disease

Japanese Sakigake designation awarded to Opdivo for biliary tract cancer

Subgroups benefit from lefitolimod in phase II IMPULSE trial in small-cell lung cancer

Denovo gains exclusive worldwide license to liafensine

CSPC Zhongqi Pharmaceutical Technology identifies MAPK14 inhibitors

Rhythm Pharmaceuticals patents melanocortin MC4 receptor agonists

Novartis and Amgen expand commercialization agreement for AMG-334

Five drugs assigned target products under Japanese Sakigake designation system

Cetirizine evaluated as add-on treatment for neuromyelitis optica

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.